Canada markets closed

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315.HK)

HKSE - HKSE Delayed Price. Currency in HKD
Add to watchlist
7.650+0.250 (+3.38%)
At close: 04:08PM HKT
Currency in HKD

Valuation Measures4

Market Cap (intraday) 5.25B
Enterprise Value 5.40B
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)3.95
Price/Book (mrq)3.61
Enterprise Value/Revenue 7.01
Enterprise Value/EBITDA -32.96

Trading Information

Stock Price History

Beta (5Y Monthly) N/A
52-Week Change 3-62.50%
S&P500 52-Week Change 322.55%
52 Week High 321.250
52 Week Low 35.740
50-Day Moving Average 38.558
200-Day Moving Average 310.239

Share Statistics

Avg Vol (3 month) 3133.1k
Avg Vol (10 day) 3131.9k
Shares Outstanding 5109.63M
Implied Shares Outstanding 6399.4M
Float 843.02M
% Held by Insiders 138.76%
% Held by Institutions 118.37%
Shares Short 4N/A
Short Ratio 4N/A
Short % of Float 4N/A
Short % of Shares Outstanding 4N/A
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Currency in CNY.

Fiscal Year

Fiscal Year Ends Dec 31, 2023
Most Recent Quarter (mrq)Dec 31, 2023

Profitability

Profit Margin -53.42%
Operating Margin (ttm)-34.67%

Management Effectiveness

Return on Assets (ttm)-6.94%
Return on Equity (ttm)-39.45%

Income Statement

Revenue (ttm)716.91M
Revenue Per Share (ttm)1.80
Quarterly Revenue Growth (yoy)28.00%
Gross Profit (ttm)N/A
EBITDA -151.63M
Net Income Avi to Common (ttm)-382.95M
Diluted EPS (ttm)-1.030
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)434.04M
Total Cash Per Share (mrq)1.09
Total Debt (mrq)544.11M
Total Debt/Equity (mrq)68.84%
Current Ratio (mrq)1.25
Book Value Per Share (mrq)1.97

Cash Flow Statement

Operating Cash Flow (ttm)-76.65M
Levered Free Cash Flow (ttm)-231.5M